Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
1.
Clin Transl Oncol ; 23(2): 311-317, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32562197

RESUMO

PURPOSE: Baseline LDH, derived neutrophil-lymphocyte ratio (dNLR) and immune-related adverse events (irAEs) are associated with outcomes of patients with metastatic melanoma (MM). We hypothesized whether dynamic shifts in LDH, dNLR and incidence of irAEs may impact the prognosis of MM patients treated with anti-CTLA4 or anti-PD1 as single agents. METHODS: Retrospective analysis of medical charts from MM patients with prospective monitoring of dNLR, LDH values and irAE incidence. Primary endpoint was overall survival (OS). RESULTS: Patients switching from either high dNLR (≥2.5) to low dNLR (HR: 0.14; 0.03-0.74; p = 0.02) or high LDH (≥1.5 × ULN) to low LDH levels (HR: 0.08; 0.01-0.68; p = 0.02) had significantly better OS than those with high dNLR or LDH scores at the end of cycle 2. Longer OS was also observed in patients developing irAEs ≥ grade 2 as compared to no irAEs (HR: 0.2; 0.05-0.89; p = 0.03). CONCLUSIONS: We found that major shifts in dNLR and LDH measures from baseline to cycle 2 measures and shifts from baseline to cycle 2 are significantly associated with OS in MM patients receiving single agent anti-PD1 therapy. Laboratory changes and clinical variables may help optimize prognostic estimates.


Assuntos
Biomarcadores Tumorais/sangue , Imunoterapia , Lactato Desidrogenases/sangue , Linfócitos/citologia , Melanoma/mortalidade , Neutrófilos/citologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados/uso terapêutico , Feminino , Humanos , Inibidores de Checkpoint Imunológico/uso terapêutico , Imunoterapia/efeitos adversos , Ipilimumab/uso terapêutico , Masculino , Melanoma/sangue , Melanoma/secundário , Melanoma/terapia , Pessoa de Meia-Idade , Nivolumabe/uso terapêutico , Estudos Prospectivos , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
2.
Actas Dermosifiliogr (Engl Ed) ; 111(10): 815-821, 2020 Dec.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-32910922

RESUMO

Teledermatology has facilitated specialist care during the crisis caused by the coronavirus disease 2019 pandemic, eliminating unnecessary office visits and the possible exposure of patients or dermatologists. However, teledermatology brings forward certain ethical and medicolegal questions. A medical consultation in which the patient is not physically present is still a medical act, to which all the usual ethical and medicolegal considerations and consequences apply. The patient's right to autonomy and privacy, confidentiality, and data protection must be guaranteed. The patient must agree to remote consultation by giving informed consent, for which a safeguard clause should be included. Well-defined practice guidelines and uniform legislation are required to preserve the highest level of safety for transferred data. Adequate training is also needed to prevent circumstances involving what might be termed «telemalpractice¼.


Assuntos
COVID-19/epidemiologia , Pandemias , SARS-CoV-2 , Telemedicina , Lista de Checagem , Confidencialidade , Atenção à Saúde/legislação & jurisprudência , Dermatologia/ética , Dermatologia/legislação & jurisprudência , Dermatologia/métodos , Medicina Baseada em Evidências , Humanos , Consentimento Livre e Esclarecido , Imperícia , Aceitação pelo Paciente de Cuidados de Saúde , Autonomia Pessoal , Espanha/epidemiologia , Telemedicina/ética , Telemedicina/legislação & jurisprudência , Telemedicina/métodos
4.
Actas Dermosifiliogr (Engl Ed) ; 110(8): 659-665, 2019 Oct.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31153547

RESUMO

BACKGROUND AND OBJECTIVE: Skin lesions are a common reason for consulting a primary care physician. Current legislation in Spain states that purely aesthetic skin problems that do not pose a health problem are not to be treated within the National Health Service. The aim of this study was to estimate the proportion of referrals from primary care physicians to dermatologists that were for cystic lesions or benign tumors and could potentially have been avoided. MATERIAL AND METHODS: We consulted cases registered in the DIADERM study dataset, which is representative of dermatology practice in Spain, and collected the main diagnoses given on referring patients from primary care. A referral diagnosis was classified as potentially avoidable if it corresponded to one of the primary care discharge diagnoses listed in a consensus paper of the Andalusian section of the Spanish Academy of Dermatology and Venereology (AEDV). RESULTS: We collected 2171 main reasons for first-visit referrals to dermatologists; 686 of them (31.6%) were for cystic lesions or benign tumors and classified as potentially avoidable. In 478 cases (22%) the patients were discharged on the first visit. The most frequent diagnoses in such cases were seborrheic keratosis (9.3%) and melanocytic nevus (8.6%). CONCLUSIONS: Nearly a third of referrals from primary care to a dermatologist were for cystic lesions and benign tumors and could have been avoided. A clearer understanding of our caseload can be useful for improving planning, training, and health care system management.


Assuntos
Dermatologia/estatística & dados numéricos , Mau Uso de Serviços de Saúde/estatística & dados numéricos , Atenção Primária à Saúde/estatística & dados numéricos , Encaminhamento e Consulta/estatística & dados numéricos , Dermatopatias/diagnóstico , Cistos/diagnóstico , Mau Uso de Serviços de Saúde/prevenção & controle , Humanos , Ceratose Seborreica/diagnóstico , Espanha
5.
Clin Exp Dermatol ; 44(4): e103-e109, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30701578

RESUMO

BACKGROUND: Solid-organ transplant recipients (SOTRs) are at risk of developing vitamin D deficiency, mainly caused by reduced sunlight exposure with subsequent low vitamin D synthesis in the skin. AIM: To analyse whether SOTRs from a Spanish Mediterranean region were vitamin D-deficient. METHODS: This was a cross-sectional, descriptive and observational study in a transplantation-specialized Dermatological Unit from a Mediterranean area to determine the calcidiol levels of a cohort of 78 consecutively attending patients not receiving vitamin D supplements. Serum 25(OH)D3 levels were determined and clinical characteristics were collected. Logistic regression analysis was used to analyse variables associated with dichotomized 25(OH)D3 levels (≤ or > 10 ng/mL). RESULTS: The cohort comprised 30 lung, 29 kidney and 19 liver transplant recipients. Mean calcidiol was 18 ± 9 ng/mL. Deficiency of 25(OH)D3 was present in 19% of patients, while 68% had insufficient levels and 13% had sufficient levels. Following multivariate logistic regression analysis, the season of blood sampling remained the only predictor of deficient 25(OH)D3 levels. CONCLUSION: Despite living in a mid-latitude country with sunny weather, our SOTR population was at high risk of developing hypovitaminosis D, especially in autumn/winter. Avoiding sun exposure is important to prevent skin cancer, but careful monitoring of vitamin D status is recommended, with supplementation if hypovitaminosis D is detected.


Assuntos
Luz Solar/efeitos adversos , Transplantados/estatística & dados numéricos , Transplantes/estatística & dados numéricos , Deficiência de Vitamina D/etiologia , Adulto , Idoso , Calcifediol/sangue , Estudos Transversais , Feminino , Humanos , Masculino , Região do Mediterrâneo/epidemiologia , Pessoa de Meia-Idade , Fatores de Risco , Estações do Ano , Espanha/epidemiologia , Transplantes/metabolismo , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/epidemiologia
6.
Oncogene ; 36(41): 5695-5708, 2017 10 12.
Artigo em Inglês | MEDLINE | ID: mdl-28581514

RESUMO

Despite the promising targeted and immune-based interventions in melanoma treatment, long-lasting responses are limited. Melanoma cells present an aberrant redox state that leads to the production of toxic aldehydes that must be converted into less reactive molecules. Targeting the detoxification machinery constitutes a novel therapeutic avenue for melanoma. Here, using 56 cell lines representing nine different tumor types, we demonstrate that melanoma cells exhibit a strong correlation between reactive oxygen species amounts and aldehyde dehydrogenase 1 (ALDH1) activity. We found that ALDH1A3 is upregulated by epigenetic mechanisms in melanoma cells compared with normal melanocytes. Furthermore, it is highly expressed in a large percentage of human nevi and melanomas during melanocyte transformation, which is consistent with the data from the TCGA, CCLE and protein atlas databases. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. Interestingly, DIMATE also targeted the slow cycling label-retaining tumor cell population containing the tumorigenic and chemoresistant cells. Our findings suggest that aldehyde detoxification is relevant metabolic mechanism in melanoma cells, which can be used as a novel approach for melanoma treatment.


Assuntos
Aldeído Oxirredutases/genética , Alcinos/administração & dosagem , Melanócitos/efeitos dos fármacos , Melanoma/tratamento farmacológico , Compostos de Sulfidrila/administração & dosagem , Aldeído Oxirredutases/antagonistas & inibidores , Animais , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Transformação Celular Neoplásica/efeitos dos fármacos , Transformação Celular Neoplásica/genética , Epigênese Genética , Regulação Neoplásica da Expressão Gênica , Humanos , Melanócitos/patologia , Melanoma/genética , Melanoma/patologia , Camundongos , Células-Tronco Neoplásicas/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto
9.
Actas Dermosifiliogr ; 107(2): 125-32, 2016 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-26691244

RESUMO

BACKGROUND: Skin problems are among the most frequent reasons for seeking medical attention in primary care. In recent years, as a result of the process of adapting medical curricula to the requirements of the European Higher Education Area, the amount of time students spend learning the concepts of dermatology has been reduced in many universities. MATERIAL AND METHODS: In order to reach a consensus on core content for undergraduate education in dermatology, we sent a survey to the 57 members of the instructors' group of the Spanish Academy of Dermatology and Venereology (AEDV), asking their opinions on what objectives should be set for a dermatology course in Spain. A total of 131 previously selected objectives were listed. We then applied the Delphi method to achieve consensus on which ones the respondents considered important or very important (score≥4 on a Likert scale). RESULTS: Nineteen responses (33%) were received. On the second round of the Delphi process, 68 objectives achieved average scores of at least 4. The respondents emphasized that graduates should understand the structure and functions of the skin and know about bacterial, viral, and fungal skin infections, the most common sexually transmitted diseases (STDs), and the 4 main inflammatory dermatoses. Students should also learn about common complaints, such as itching and bald patches; the management of dermatologic emergencies; purpura and erythema nodosum as signs of internal disease; and the prevention of STDs and skin cancer. During clinical clerkships students should acquire the communication skills they will need to interview patients, write up a patient's medical history, and refer the patient to a specialist. CONCLUSIONS: The AEDV's group of instructors have defined their recommendations on the core content that medical faculties should adopt for the undergraduate subject of dermatology in Spain.


Assuntos
Currículo , Dermatologia/educação , Educação de Graduação em Medicina , Venereologia/educação , Humanos , Espanha
10.
J Eur Acad Dermatol Venereol ; 29(1): 56-60, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24629001

RESUMO

INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic skin disease which causes a great impact in the quality of life. Multiple therapeutic options have been proposed, and recently the potential use of biological drugs in severe cases has been postulated. MATERIAL AND METHODS: A retrospective study from seven tertiary Spanish centers reviewing the charts of patients with HS treated with biological drugs was performed. Retrieved information included epidemiological data, clinical features, pain intensity, Hurley stage, laboratory data and therapeutic outcomes. RESULTS: Nineteen patients were included in the study; 10 men (52.6%) and 9 women. Eight patients (42%) showed a Hurley severity stage II and 11 a stage III (57.8%). Adalimumab was prescribed as the first biological treatment in nine out of 19 cases (47.3%), whereas infliximab was prescribed in seven cases (36.8%), ustekinumab in two cases (10.5%) and etanercept in one (5.2%). A complete response was observed in three patients (two cases with infliximab and one case with ustekinumab), a partial improvement in 10 patients and in six patients no clinical improvement was noted. One patient referred worsening of the skin symptoms. In 6 cases, a second biological treatment was prescribed. In three of such cases, a partial improvement was noted, whereas in three cases no clinical improvement was observed. In two cases a switch to a third biological drug was indicated, with a partial improvement in one case. DISCUSSION AND CONCLUSIONS: Biological drugs could be a potential and effective therapeutic option for patients with severe HS. Complete and persistent clinical responses are rarely obtained (15%) and partial responses are achieved in approximately 50% of patients. No specific markers for a therapeutic response have been identified. No definitive conclusions regarding the most effective biological drug for HS could be drawn. Higher dosage schedules seem to be associated with higher response rates. The lack of response of one particular drug does not preclude a potential efficacy to another biological treatment.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Terapia Biológica , Hidradenite Supurativa/tratamento farmacológico , Imunoglobulina G/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Adalimumab , Adolescente , Adulto , Substituição de Medicamentos , Etanercepte , Feminino , Humanos , Infliximab , Masculino , Estudos Retrospectivos , Índice de Gravidade de Doença , Resultado do Tratamento , Ustekinumab , Adulto Jovem
13.
Arch Dermatol Res ; 306(1): 93-5, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24173126

RESUMO

The association between beta human papillomavirus (HPV) types and cutaneous squamous cell carcinomas (cSCCs) is controversial. Several studies have found such an association, especially at early stages of carcinogenesis, but the presence of beta HPV types in aggressive cSCCs has only been reported in three patients previously. We aimed to search for beta HPV DNA in primary cSCCs and their corresponding lymph node metastases in a series of patients. The presence of DNA from 25 beta HPV types was determined using a multiplex PCR protocol in 35 primary cSCCs from 35 patients and their corresponding lymph node metastases. DNA from beta HPV types was detected in 9 % of primary cSCCs and in 13 % of metastases. No primary cutaneous SCC or lymphatic metastases were found to share the same HPV DNA. These data suggest that beta HPV types do not play an etiopathogenic role in advanced stages of squamous cell carcinogenesis.


Assuntos
Betapapillomavirus/genética , Carcinoma de Células Escamosas/genética , Metástase Linfática/genética , Infecções por Papillomavirus/genética , Neoplasias Cutâneas/genética , Idoso , Idoso de 80 Anos ou mais , Betapapillomavirus/classificação , Betapapillomavirus/isolamento & purificação , Carcinoma de Células Escamosas/virologia , DNA Viral , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Papillomavirus/virologia , Neoplasias Cutâneas/virologia
14.
Actas Dermosifiliogr ; 104(8): 694-709, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24018211

RESUMO

Biologic therapy is a well-established strategy for managing moderate and severe psoriasis. Nevertheless, the high cost of such therapy, the relatively short span of clinical experience with biologics, and the abundance of literature now available on these agents have made evidence-based and consensus-based clinical guidelines necessary. The ideal goal of psoriasis treatment is to achieve complete or nearly complete clearing of lesions and to maintain it over time. Failing that ideal, the goal would be to reduce involvement to localized lesions that can be controlled with topical therapy. Although current evidence allows us to directly or indirectly compare the efficacy or risk of primary or secondary failure of available biologics based on objective outcomes, clinical trial findings cannot be directly translated to routine practice. As a result, the prescribing physician must tailor the treatment regimen to the individual patient. This update of the clinical practice guidelines issued by the Spanish Academy of Dermatology and Venereology (AEDV) on biologic therapy for psoriasis incorporates information from the most recent publications on this topic.


Assuntos
Fatores Biológicos/uso terapêutico , Medicina Baseada em Evidências , Psoríase/tratamento farmacológico , Acitretina/uso terapêutico , Adulto , Fatores Etários , Artrite Psoriásica/tratamento farmacológico , Fatores Biológicos/efeitos adversos , Fatores Biológicos/economia , Criança , Ensaios Clínicos como Assunto , Terapia Combinada , Análise Custo-Benefício , Substituição de Medicamentos , Feminino , Humanos , Imunossupressores/uso terapêutico , Masculino , Metanálise como Assunto , Estudos Multicêntricos como Assunto , Fotoquimioterapia , Gravidez , Complicações na Gravidez/tratamento farmacológico , Índice de Gravidade de Doença , Fatores Sexuais , Espanha , Falha de Tratamento , Resultado do Tratamento
15.
Actas Dermosifiliogr ; 104(10): 890-6, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23809583

RESUMO

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a rare disease that represents a heavy burden for both the patient and the health care system. There are currently no data on the prevalence of DEB in Spain. OBJECTIVE: To determine the prevalence of DEB in Spain. METHODS: We used data from 3 incomplete population-based sources (hospital dermatology departments, diagnostic laboratories performing antigenic mapping, genetic testing or both, and the Spanish Association of Epidermolysis Bullosa Patients [DEBRA]) and combined them using the 3-source capture-recapture methodology. RESULTS: We identified 152 living DEB patients. The estimated prevalence of DEB was 6.0 cases per million (95% CI, 4.2-11.8) in adults and 15.3 (95% CI, 10.4-40.8) in children under 18 years of age. The data indicated that 77% of the patients were not being followed up in specialized centers of reference; 65% had not had a genetic diagnosis, and 76% were not members of DEBRA. CONCLUSIONS: The prevalence of DEB in Spain is 6.0 patients per million (95% CI, 4.2-11.8), a figure higher than previous estimates in many areas, but similar to those found in other southern Europe countries. The north-south difference may represent real geographic differences in prevalence, but it might be due to the fact that most of the data come from registries with a lower than expected catchment. Many patients are not being followed up in centers of reference, do not have genetic diagnosis, and are not members of patients' associations, suggesting that there is room for considerable improvement in their care.


Assuntos
Epidermólise Bolhosa Distrófica/epidemiologia , Epidermólise Bolhosa Distrófica/terapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Estudos Transversais , Necessidades e Demandas de Serviços de Saúde/estatística & dados numéricos , Humanos , Lactente , Pessoa de Meia-Idade , Prevalência , Estudos Prospectivos , Melhoria de Qualidade , Espanha/epidemiologia , Adulto Jovem
16.
Actas Dermosifiliogr ; 104(2): 133-40, 2013 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-22835227

RESUMO

BACKGROUND: Complete surgical excision is the most common treatment for basal cell carcinoma (BCC), and this intervention is often performed by surgeons who are not dermatologists (e.g., plastic surgeons, general surgeons, oral and maxillofacial surgeons, ophthalmologists, and otorhinolaryngologists). OBJECTIVES: To determine positive margin rates in BCCs removed by surgeons from different specialties and to identify clinical and pathologic factors that might explain potential differences between specialties. METHODS: We retrospectively reviewed the pathology reports of all BCCs diagnosed at Hospital Universitari Vall d'Hebron between January 2009 and March 2001. The statistical methods included a descriptive analysis of clinical and pathologic variables, standard statistical analyses, and multivariate logistic regression. RESULTS: We included 921 BCCs from 750 patients; 549 of the tumors had been excised by a dermatologist. The overall positive margin rate was 12.6%, but the rate for tumors removed by dermatologists was significantly lower than that for those removed by other specialists (6.7% vs 21.5%). There was a 3.8-fold increased relative risk of positive margins following excision by a surgeon who was not a dermatologist, independently of patient age, tumor site, maximum diameter of the resected specimen, and histologic subtype. CONCLUSIONS: Accurate macroscopic identification of tumor margins, which are often difficult to see, and familiarity with the natural history of BCC are key factors in the successful surgical treatment of BCCs. The higher rate of tumor-free margins achieved by dermatologists in this study is probably mainly due to their greater experience in these 2 areas.


Assuntos
Carcinoma Basocelular/patologia , Carcinoma Basocelular/cirurgia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgia , Idoso , Feminino , Humanos , Masculino , Estudos Retrospectivos , Especialidades Cirúrgicas
17.
Actas Dermosifiliogr ; 103(6): 478-87, 2012.
Artigo em Espanhol | MEDLINE | ID: mdl-22261674

RESUMO

Penile squamous cell carcinoma (SCC) is uncommon in Europe, where it accounts for approximately 0.7% of all malignant tumors in men. The main risk factors are poor hygiene, lack of circumcision, human papillomavirus (HPV) infection, and certain chronic inflammatory skin diseases. HPV infection is detected in 70% to 100% of all penile in situ SCCs and in 30% to 50% of invasive forms of the disease, mainly basaloid and warty SCCs. In situ tumors can be treated conservatively, but close monitoring is essential as they become invasive in between 1% and 30% of cases. The treatment of choice for penile SCC is surgery. Inguinal lymph node irradiation is no longer recommended as a prophylactic measure, and it appears that selective lymph node biopsy might be useful for reducing the morbidity associated with prophylactic inguinal lymph node dissection. Survival is directly related to lymph node involvement. Improving our knowledge of underlying molecular changes and their associated genotypes will open up new therapeutic pathways.


Assuntos
Carcinoma de Células Escamosas/epidemiologia , Neoplasias Penianas/epidemiologia , Idoso , Balanite (Inflamação)/complicações , Balanite (Inflamação)/patologia , Carcinoma in Situ/epidemiologia , Carcinoma in Situ/cirurgia , Carcinoma in Situ/virologia , Carcinoma de Células Escamosas/cirurgia , Carcinoma de Células Escamosas/virologia , Circuncisão Masculina , Condiloma Acuminado/epidemiologia , Condiloma Acuminado/virologia , Europa (Continente)/epidemiologia , Papillomavirus Humano 16/patogenicidade , Humanos , Higiene , Excisão de Linfonodo , Metástase Linfática , Masculino , Invasividade Neoplásica , Estadiamento de Neoplasias , Infecções por Papillomavirus/epidemiologia , Neoplasias Penianas/classificação , Neoplasias Penianas/prevenção & controle , Neoplasias Penianas/cirurgia , Neoplasias Penianas/virologia , Fimose/complicações , Fimose/patologia , Lesões Pré-Cancerosas/epidemiologia , Lesões Pré-Cancerosas/patologia , Prognóstico , Fatores de Risco
18.
Br J Dermatol ; 166(4): 830-8, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22121851

RESUMO

BACKGROUND: Conradi-Hünermann-Happle syndrome (CDPX2, OMIM 302960) is an inherited X-linked dominant variant of chondrodysplasia punctata which primarily affects the skin, bones and eyes. CDPX2 results from mutations in EBP (emopamil binding protein), and presents with increased levels of sterol precursors 8(9)-cholesterol and 8-dehydrocholesterol. OBJECTIVES: To expand the understanding of CDPX2, clinically, biochemically and genetically. METHODS: We present one of the largest series reported to date, including 13 female patients belonging to nine Spanish families. Patients were studied biochemically using gas chromatography-mass spectrometry, genetically using polymerase chain reaction and in their methylation status using the HUMARA assay. RESULTS: In our cases, there was a clear relationship between abnormal sterol profile and the EBP gene mutation. We describe three novel mutations in the EBP gene. EBP mutations were inherited in three out of nine families and were sporadic in the remaining cases. CONCLUSIONS: No clear genotype-phenotype correlation was found. Patients' biochemical profiles did not reveal a relationship between sterol profiles and severity of disease. A skewed X-chromosome inactivation may explain the clinical phenotype in CDPX2 in some familial cases.


Assuntos
Condrodisplasia Punctata/genética , Doenças Genéticas Ligadas ao Cromossomo X/genética , Mutação/genética , Esteroide Isomerases/genética , Inativação do Cromossomo X/genética , Adulto , Colestadienóis/metabolismo , Colesterol/metabolismo , Condrodisplasia Punctata/metabolismo , Análise Mutacional de DNA/métodos , Feminino , Doenças Genéticas Ligadas ao Cromossomo X/metabolismo , Genótipo , Humanos , Lactente , Fenótipo , Espanha
19.
J Eur Acad Dermatol Venereol ; 25(10): 1153-9, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21198948

RESUMO

BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening drug reactions considered to be part of the spectrum of a single pathological process. OBJECTIVE: To describe the clinical and epidemiological characteristics of SJS/TEN in children attended at our hospital. MATERIALS AND METHODS: Retrospective study of children diagnosed with SJS/TEN between 1999 and 2009 in a University Hospital provided with regional-level burn and paediatric intensive care units. RESULTS: We found 14 paediatric patients (eight SJS and six TEN). They presented an average of 60% of the body surface area affected and 31% of epidermal sloughing. The average of suspected drugs was 1.7 per patient, anticonvulsants (carbamazepine, phenytoin and lamotrigine) and antibiotics (penicillin and macrolides) being the most frequent ones. Silver sulfadiazine was the topical treatment most frequently used, 86% of patients received systemic steroids and 28.5% intravenous immunoglobulins. One patient died. CONCLUSIONS: The SJS/TEN complex is a true dermatological critical condition that also affects children. Any drug can be the causative agent, more frequently anticonvulsants and antibiotics. Depending on the extension of the affected body surface, patients should be rapidly admitted to a critical care area with experience in the care of burn patients. Discontinuation of the suspected offending drugs is mandatory. Optimal supportive care and management of denuded skin areas are still the mainstay of treatment. The use of specific therapies remains controversial. Compared with adults, the disease in children seems to be milder with lower mortality.


Assuntos
Síndrome de Stevens-Johnson , Adolescente , Corticosteroides/uso terapêutico , Antibacterianos/efeitos adversos , Anticonvulsivantes/efeitos adversos , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Feminino , Humanos , Incidência , Lactente , Masculino , Estudos Retrospectivos , Síndrome de Stevens-Johnson/tratamento farmacológico , Síndrome de Stevens-Johnson/epidemiologia , Síndrome de Stevens-Johnson/etiologia , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA